Spruce Biosciences' expanded access program for tralesinidase alfa in MPS IIIB listed as available
Registry record posted July 29, 2026 shows intracerebroventricular enzyme therapy accessible to Sanfilippo Syndrome Type B patients outside of a formal trial.
Spruce Biosciences has a registered expanded access record for its MPS IIIB program, posted July 29, 2026 and updated September 21, 2026.
- Tralesinidase alfa (TA), an early access program (EAP), for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B): status listed as available. The program provides access to intracerebroventricular tralesinidase alfa for participants with MPS IIIB.1 Approximately 10 participants will be enrolled at up to 3 US sites and treated with TA once weekly via ICV infusion for up to approximately 52 weeks, or until TA becomes commercially available.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.